Nuon Therapeutics, Inc.

Nuon Therapeutics was a clinical-stage biotechnology company focused on developing innovative small molecule drugs for autoimmune diseases, chronic inflammatory conditions, and pain. Its lead compound was tranilast, an orally available drug with a novel mechanism targeting activated T-cells/B-cells via the TGF-beta pathway. Tranilast advanced through at least one completed Phase II trial for gout/hyperuricemia in combination with allopurinol, with additional development efforts targeting rheumatoid arthritis, multiple sclerosis, neuropathic pain, and other autoimmune indications. The company also explored combinations such as allopurinol/tranilast for hyperuricemia/gout.